Therakos
Raritan
About Therakos
Therakos provides extracorporeal photopheresis immune modulation therapy to enhance immunologic response. It offers Therakos Cellex Photopheresis System, which is used in conjunction with UVADEX (methoxsalen) Sterile Solution to treat the skin manifestations of CTCL that are unresponsive to other forms of treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 10,001+
- Estimated revenue: $10K – $50K
- Website: therakos.com
- Phone: 4846311000
Industries & Categories
Health Care, Medical, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/therakos-2735246 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.